Difference between revisions of "Part:BBa K2686000"
(→Expression) |
(→Assembly) |
||
Line 40: | Line 40: | ||
The self assembly of the encapsulin 60-mer was first examined using PAGE, where the monomer is seen around 32.9kDa as well as a high band due to the high molecular weight and size of the 1.98MDa complex, showing that the 60-mer is present. | The self assembly of the encapsulin 60-mer was first examined using PAGE, where the monomer is seen around 32.9kDa as well as a high band due to the high molecular weight and size of the 1.98MDa complex, showing that the 60-mer is present. | ||
− | [[File:NativeGel.png|thumb|center|upright=3|Native PAGE gel of sfGFP, HexaHistidine-OT1 Encapsulin and HexaHistidine-OT1 Encapsulin sfGFP-tag. On the '''left''' is the fluorescent image of the gel and o the '''right''' is the gel after Coomassie staining. '''Before''' ('''B''') heat purification procedure outlined in '''Purification''' section, '''Supernatant''' ('''S''') after the heat purification procedure. '''Stars''' <nowiki>★</nowiki> show the bands for monomers of HexaHistidine-OT1 Encapsulin ( | + | [[File:NativeGel.png|thumb|center|upright=3|Native PAGE gel of sfGFP, HexaHistidine-OT1 Encapsulin and HexaHistidine-OT1 Encapsulin sfGFP-tag. On the '''left''' is the fluorescent image of the gel and o the '''right''' is the gel after Coomassie staining. '''Before''' ('''B''') heat purification procedure outlined in '''Purification''' section, '''Supernatant''' ('''S''') after the heat purification procedure. '''Stars''' <nowiki>★</nowiki> show the bands for monomers of HexaHistidine-OT1 Encapsulin (<bbpart>BBa_K2686000</bbpart>,<bbpart>BBa_K2686006</bbpart>) with sfGFP-tag bound to them, increasing the molecular weight of the complex when compared to sfGFP alone. '''Triangles''' <nowiki>▲</nowiki> signify a 60-mer band to the right. |
− | From left to right: '''(1-2)''' Negative control (cell-free TX-TL expression without DNA), '''(2-4)''' HexaHistidine-OT1 Encapsulin ( | + | From left to right: '''(1-2)''' Negative control (cell-free TX-TL expression without DNA), '''(2-4)''' HexaHistidine-OT1 Encapsulin (<bbpart>BBa_K2686000<bbpart>), showing no fluorescence on the left gel, has a band for 60-mer on stained gel (<nowiki>▲</nowiki>). '''(5-6)''' sfGFP protein, the fluorescent bands can be easily seen as large smears on the left. '''(7-8)''' HexaHistidine-OT1 Encapsulin and sfGFP-tag (<bbpart>BBa_K2686006</bbpart>) shown by a <nowiki>★</nowiki>. The difference in height between the bands of sfGFP compared to the <nowiki>★</nowiki> is striking and suggests that the sfGFP-tag binds to the HexaHistidine-OT1 Encapsulin monomers. In addition there seems to be a small amount of 60-mer indicated by <nowiki>▲</nowiki>. '''(9-10)''' Encapsulin (<bbpart>BBa_K2686001</bbpart>) does assemble to form the 60-mer <nowiki>▲</nowiki> as seen on the stained gel. '''(11)''' HexaHistidine-OT1 Encapsulin and sfGFP-tag (<bbpart>BBa_K2686006</bbpart>), on the left the presumed <nowiki>★</nowiki> protein dimer is seen to be higher than the sfGFP in lane '''12''', no particular bands can be identified on the right. '''(12)''' sfGFP, fluorescent band is seen to be lower than for lane '''11'''. |
]] | ]] | ||
Revision as of 10:59, 17 October 2018
Encapsulin with HexaHistidine insert and C-terminal OT1
This part encodes a modified Thermotoga maritima Encapsulin protein. The part is optimized for expression in E. coli and has an additional HexaHistidine (GGGGGGHHHHHHGGGGG) insert between amino acids 43 and 44, forming a loop on the interior surface of the encapsulin monomer providing higher heat resistance and stability, and better hydrodynamic properties (Moon et al., 2014). The C-terminus of the encapsulin is fused to a SIINFEKL (OT1) peptide which is displayed on the exterior surface of the encapsulin monomer as an antigen (Choi et al., 2016). SIINFEKL was chosen as it is a very popular model antigen sequence in research and a variety of antibodies targeting it are available, furthermore it is used as a tumor antigen model in scientific research and has been used in conjunction with encapsulin (Choi et al., 2016).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 77
Illegal BglII site found at 492 - 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 426
Illegal SapI.rc site found at 457
Characterization
A variety of different characterization techniques were used to assess the properties of the encapsulin protein cage.
Expression
A cell free expression system was used to synthesize the encapsulin proteins in vitro. The TX-TL cell free system is a robust way to express proteins (Sun et al., 2013), and was used by last year's EPFL iGEM team Aptasense.
Purification
After having tested a variety of purification procedures, heat purification at 70C for 20 minutes followed by cooling on ice for 15 minutes and a subsequent centrifugation at 12000g for 10 minutes was found to be the most efficient way of isolating the encapsulin (encapsulin ends up in supernatant).
Assembly
The self assembly of the encapsulin 60-mer was first examined using PAGE, where the monomer is seen around 32.9kDa as well as a high band due to the high molecular weight and size of the 1.98MDa complex, showing that the 60-mer is present.
Dendritic Cell Uptake
References
Choi, B., Moon, H., Hong, S., Shin, C., Do, Y., Ryu, S. and Kang, S. (2016). Effective Delivery of Antigen–Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection. ACS Nano, 10(8), pp.7339-7350.
Moon, H., Lee, J., Min, J. and Kang, S. (2014). Developing Genetically Engineered Encapsulin Protein Cage Nanoparticles as a Targeted Delivery Nanoplatform. Biomacromolecules, 15(10), pp.3794-3801.
Shimizu, Y., Inoue, A., Tomari, Y., Suzuki, T., Yokogawa, T., Nishikawa, K. and Ueda, T. (2001). Cell-free translation reconstituted with purified components. Nature Biotechnology, 19(8), pp.751-755.
Sun, Z., Hayes, C., Shin, J., Caschera, F., Murray, R. and Noireaux, V. (2013). Protocols for Implementing an Escherichia coli Based TX-TL Cell-Free Expression System for Synthetic Biology. Journal of Visualized Experiments, (79).